Fundraising Fox

Mulberry Biotherapeutics

Wellesley, US · Founded 2020 · Delaware corporation

mulberrybio.com ↗

Mulberry Biotherapeutics develops bacteria-mediated immunotherapies using genetically engineered, live-attenuated Salmonella Typhimurium injected directly into tumors to treat rare, slow-growing tumors. Its lead program, MUL001, targets Neurofibromatosis type 2-related schwannomatosis (NF2-SWN), with planned follow-on indications including NF1-associated nerve sheath tumors and meningiomas.

BiotechHealthtech

Founders & leadership

Mulberry Biotherapeutics was founded in 2020 by Gary Brenner and John Mekalanos.

GB
Gary BrennerFounder
JM
John MekalanosFounder
NK
Neil KirbyCEO and Board Member
SL
Susan LuoExecutive

Board

PR
Philip R. ReillyBoard director

Reported raises · per SEC filings

Form D private placements

$2.1M disclosed across 1 round · 2021

▶$2.1MraisedApr 2021 · 17 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Neil KirbyExecutive Officer
  • Susan LuoExecutive Officer
  • Philip R. ReillyDirector
Offering amount
$2.8M
Amount sold
$2.1M
First sale
Apr 2021
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 5

by search overlap
Mission BioCapital Platinum Program Holdings LLC4 shared keywordsMission BioCapital is an early-stage venture capital firm that provides capital and shared lab space to life science startups, supporting founders from initial experiments through to the clinic. Founded in 2009, it invests in early-stage life science companies and is currently deploying its fifth fund.
Modulate Bio3 shared keywordsModulate Bio develops small-molecule GABAA positive allosteric modulators to treat neurological disorders including Essential Tremor, epilepsy, and anxiety. Its drug-discovery platform aims to selectively activate specific GABAA receptor subunits to provide efficacy while limiting side effects.
Orum Therapeutics Venture Capital3 shared keywordsOrum Rx is a clinical-stage biotech company developing a novel class of antibody-drug conjugates (ADCs) that pair antibody targeting with protein degraders. Its cell-selective degradation approach aims to improve the efficacy, safety, and half-life of conventional targeted protein degraders for disease treatment.
Transcode Therapeutics3 shared keywordsTransCode Therapeutics is a clinical-stage company developing immuno-oncology and RNA-based therapeutics for high-risk and advanced cancers. Its lead candidate, TTX-MC138, targets microRNA-10b to treat patients with metastatic cancer and is in Phase 2a clinical trials.
Muna Therapeutics3 shared keywordsMuna Therapeutics is a biotechnology company that discovers and develops therapies aimed at slowing or stopping neurodegenerative diseases, including Alzheimer's and Parkinson's. It operates in neurology-focused drug discovery and development.

Companies competing with Mulberry Biotherapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Mulberry Biotherapeutics do?
Mulberry Biotherapeutics develops bacteria-mediated immunotherapies using genetically engineered, live-attenuated Salmonella Typhimurium injected directly into tumors to treat rare, slow-growing tumors. Its lead program, MUL001, targets Neurofibromatosis type 2-related schwannomatosis (NF2-SWN), with planned follow-on indications including NF1-associated nerve sheath tumors and meningiomas.
Who founded Mulberry Biotherapeutics?
Mulberry Biotherapeutics was founded by Gary Brenner, John Mekalanos in 2020.
How much funding has Mulberry Biotherapeutics raised?
Mulberry Biotherapeutics has disclosed $2.1M raised across 1 round.
Where is Mulberry Biotherapeutics headquartered?
Mulberry Biotherapeutics is headquartered in Wellesley, US.